Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy

Journal of Crohn's and Colitis

Volumn 7, Issue 2, 2013, Pages

  Stephens, Natasha S ^a   Siffledeen, Jesse ^b   Su, Xiaorong ^a   Murdoch, Travis B ^b   Fedorak, Richard N ^b   Slupsky, Carolyn M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

CD; IBD; Metabolomics; Metabonomics; NMR; UC

Indexed keywords

HIPPURIC ACID; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CITRIC ACID CYCLE; COLON RESECTION; CONTROLLED STUDY; CROHN DISEASE; FEMALE; HUMAN; ILEOANAL ANASTOMOSIS; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLITE; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; ULCERATIVE COLITIS; URINALYSIS;

ADULT; AGED; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; MALE; METABOLOME; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84872457485     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.04.019     Document Type: Article

References (29)

1. Sokol H., Lay C., Seksik P., Tannock G.W. Analysis of bacterial bowel communities of IBD patients: what has it revealed?. Inflamm Bowel Dis 2008, 14:858-867.
2. Farmer M., Petras R.E., Hunt L.E., Janosky J.E., Galandiuk S. The importance of diagnostic accuracy in colonic inflammatory bowel disease. Am J Gastroenterol 2000, 95:3184-3188.
3. Lee K.S., Medline A., Shockey S. Indeterminate colitis in the spectrum of inflammatory bowel disease. Arch Pathol Lab Med 1979, 103:173-176.
4. Price A. Overlap in the spectrum of non-specific inflammatory bowel disease - 'colitis indeterminate'. J Clin Pathol 1978, 31:567-577.
5. Chiang K.P., Niessen S., Saghatelian A., Cravatt B.F. An enzyme that regulates ether lipid signaling pathways in cancer annotated by multidimensional profiling. Chem Biol 2006, 13:1041-1050.
6. Holstein A., Burmeister J., Plaschke A., Rosemeier D., Widjaja A., Egberts E.-H. Autoantibody profiles in microscopic colitis. J Gastroenterol Hepatol 2006, 21:1016-1020.
7. Odunsi K., Wollman R.M., Ambrosone C.B., Hutson A., McCann S.E., Tammela J., et al. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 2005, 113:782-788.
8. Salek R.M., Maguire M.L., Bentley E., Rubtsov D.V., Hough T., Cheeseman M., et al. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol Genomics 2007, 29:99-108.
9. Slupsky C.M., Rankin K.N., Fu H., Chang D., Rowe B.H., Charles P.G.P., et al. Pneumococcal pneumonia: potential for diagnosis through a urinary metabolic profile. J Proteome Res 2009, 8:5550-5558.
10. Slupsky C.M., Steed H., Wells T.H., Dabbs K., Schepansky A., Capstick V., et al. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin Cancer Res 2010, 16:5835-5841.
11. Walsh M.C., Brennan L., Malthouse J.P.G., Roche H.M., Gibney M.J. Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. Am J Clin Nutr 2006, 84:531-539.
12. Marchesi J.R., Holmes E., Khan F., Kochhar S., Scanlan P., Shanahan F., et al. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease. J Proteome Res 2007, 6:546-551.
13. Williams H.R.T., Cox I.J., Walker D.G., North B.V., Patel V.M., Marshall S.E., et al. Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol 2009, 104:1435-1444.
14. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 315:514-514.
15. Pallis A.G., Vlachonikolis I.G., Mouzas I.A. Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece. BMC Gastroenterol 2002, 2:1.
16. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. New Engl J Med 1987, 317:1625-1629.
17. Slupsky C.M., Rankin K.N., Wagner J., Fu H., Chang D., Weljie A.M., et al. Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. Anal Chem 2007, 79:6995-7004.
18. Weljie A.M., Newton J., Mercier P., Carlson E., Slupsky C.M. Targeted profiling: quantitative analysis of 1H NMR metabolomics data. Anal Chem 2006, 78:4430-4442.
19. Naber A.H.J., de John D.J. Assessment of disease activity in inflammatory bowel disease; relevance for clinical trials. Neth J Med 2003, 61:105-110.
20. Shiomi Y., Nishiumi S., Ool M., Hatano H., Shinohara M., Yoshie T., et al. GCMS-based metabolomic study in mice with colitis induced by dextran sulfate sodium. Inflamm Bowel Dis 2011, 17:2261-2274.
21. Murdoch T.B., Fu H., MacFarlane S., Sydora B.C., Fedorak R.N., Slupsky C.M. Urinary metabolic profiles of inflammatory bowel disease in 1L-10 gene-deficient mice. Anal Chem 2008, 80:5524-5531.
22. Rutgeerts P., Peeters M., Hiele M., Vantrappen G., Pennincx F., Aerts R., et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991, 338:771-774.
23. Sokol H., Seksik P., Rigottier-Gois L., Lay C., Lepage P., Podglajen I., et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:106-111.
24. Frank D.N., St Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007, 104:13780-13785.
25. Sartor R.B. Therapeutic correction of bacterial dysbiosis discovered by molecular techniques. Proc Natl Acad Sci U S A 2008, 105:16413-16414.
26. Tedelind S., Westberg F., Kjerrulf M., Vidal A. Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 2007, 13:2826-2832.
27. Hamer H.M., Jonkers D., Venema K., Vanhoutvin S., Troost F.J., Brummer R.-J. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2007, 27:104-119.
28. Kumar A., Wu H., Collier-Hyams L.S., Kwon Y.-M., Hanson J.M., Neish A.S. The bacterial fermentation product butyrate influences epithelial signaling via reactive oxygen species-mediated changes in cullin-1 neddylation. J Immunol 2009, 182:538-546.
29. Wong J.M.W., de Souza R., Kendall C.W.C., Emam A., Jenkins D.J.A. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006, 40:235-243.